

# Research & Innovation

## 21-22 Performance Report

We are pleased to present the year end 2021/22 performance review of research activity at Sherwood Forest Hospitals NHS Foundation Trust.


The COVID-19 pandemic has brought into focus the strength and importance of Health and Social Care research in the UK. Research has made a leading contribution to the knowledge base during this time. However, the UK has learnt important lessons about where we can improve. This includes empowering healthcare and research workers to ensure they are supported and resilient to future challenges, alongside being more innovative in trial design and delivery. National policy is strengthening the importance of putting research at the heart of everything the NHS does, making it an essential and rewarding part of effective patient care

SFH research activity during the pandemic has been fundamental to improving the lives of our patients as a way to improve the detection, diagnosis, treatment and prevention of disease. The research portfolio is developing as we focus on growth in our specialities and COVID-19 research becomes business as usual. We are confident embedding clinical research as part of clinical care is achievable and delivers for patients. A key part of the journey to realising this is to build a culture across SFH and the wider system that is positive about research, where staff feel empowered and supported to take part in clinical research delivery as part of their job




# Performance


## Cumulative Monthly Recruitment 2020-21 and 2021-22



## Total Recruited




## Non-Commercial and Commercial Recruitment by Year



# Performance

Total Studies, Open, In Follow Up and Total Recruitment by Speciality



2021/22

CRN East Midlands Income

£752,652.04

2022/2023

Indicative Budget

£755,435,10

# Finance



Department of Health Funding

£20,000.00

To maintain research capability  
and capacity

2021/22

Commercial Income

£164,088.11

For re-investment into future  
research capability and capacity



# Patient Experience 2021/22

The research staff have been excellent ! Whenever I have had a query or concern they have demonstrated reassurance and always got back to me promptly. Very helpful and friendly



It was good that someone or a group of people were taking interest in my recovery and my experience of having been very ill with COVID

The research team have been very supportive. Was able to contact member of staff whenever necessary. Was kept informed about my progression and treatment all the time



- 91% of participants Agree/Strongly Agree their participation in Research has been valued
- 93% of participants would consider taking part in Research again
- All Participants Agree/Strongly Agree that they have been treated with courtesy and respect



# 2021/22 Highlights

Post pandemic renewed government commitment to support health and care research:

- Spending Review - > £300 million increase in funding, largest ever annual uplift
- Health and Care Bill – requirements for the promotion and facilitation of research within organisations such as NHSE and ICB's will be strengthened as part of legislation

Leading Research – Chief Investigator and Sponsor for a grant funded multi-site study for the first time

Influencing and informing through the Nottinghamshire ICS Research Partners Group

Development of formal partnership with NTU to increase research opportunities and clinical academic careers for Nurses, Midwives and AHP's

**Build Back Better**

**Infrastructure**

**Sponsorship**

**Integration**

**Collaboration**

Reset and Recovery – fully implemented, portfolio growth and Covid 19 research is business as usual - 30 new trials opened in year

CRF space secured - in use for existing trials with further transformation planned 22/23 to enable earlier phase research

Working across boundaries - Joint Senior Research Nurse post across primary care and SFH post active

Inclusion in NUH successful CRF re-bidding and mobile research unit